Clinical Research Directory
Browse clinical research sites, groups, and studies.
Population Pharmacokinetics of Terbinafine in Children With Tinea Capitis
Sponsor: Shandong University
Summary
The goal of this observational study is to characterize the population pharmacokinetics (PPK) of terbinafine in pediatric patients with tinea capitis, evaluate its efficacy and safety, and identify covariates affecting drug disposition in Chinese children aged 2-18 years diagnosed with tinea capitis and treated with oral terbinafine. The main questions it aims to answer are: What are the terbinafine pharmacokinetic parameters (e.g., AUC, CL, V) in children with tinea capitis, and how do they differ from adult values? Which covariates (e.g., age, body weight, CYP enzyme activity, renal function) significantly influence inter-individual variability in terbinafine PK parameters? What is the clinical efficacy (based on TSSS reduction and mycological cure rate) and safety profile of terbinafine in this pediatric population? Participants will: Undergo oral terbinafine treatment according to weight-based dosing (62.5-250 mg daily). Concentration determination is carried out using the opportunistic sampling method. Complete clinical assessments (TSSS scoring) and mycological examinations (microscopy/culture) at baseline and follow-up visits. Undergo routine laboratory tests (liver/kidney function, hematology) to monitor safety.
Key Details
Gender
All
Age Range
2 Years - 18 Years
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2021-06-15
Completion Date
2026-06-01
Last Updated
2025-07-02
Healthy Volunteers
No
Conditions
Interventions
Terbinafine Tablets
Oral administration once daily: For patients weighing \<20 kg: 62.5 mg qd; For patients weighing 20-40 kg: 125 mg qd; For patients weighing \>40 kg: 250 mg qd; Total 8 weeks.
Locations (1)
Beijing Children's Hospital, Capital Medical University
Beijing, China